52869-18-8

SSAA09E3 is a novel inhibitor of SARS-CoV replication, acting by preventing fusion of the viral membrane with the host cellular membrane.

SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM[1][2].

4°C, protect from light

[1] Ghosh AK, et al. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem. 2020 Jun 4;15(11):907-932. DOI:10.1002/cmdc.202000223
[2] Adedeji AO, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28. DOI:10.1128/JVI.00998-13